Preparation and diabetic use of Gibberellins

Details Preparation and diabetic use of Gibberellins Preparation and diabetic use of Gibberellins

2011-06-28

2011-06-28

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S025000, C514S033000

Reexamination Certificate

active

07968596

ABSTRACT:
The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like. The method results the normalization of serum glucose level and other physiological conditions.

REFERENCES:
patent: 4424232 (1984-01-01), Parkinson
patent: 4784996 (1988-11-01), White et al.
patent: 5580857 (1996-12-01), Oden
patent: 5922769 (1999-07-01), Barelli et al.
patent: 0024951 (1983-12-01), None
patent: 58-152499 (1983-10-01), None
patent: 02-065775 (1990-06-01), None
patent: WO 94/26240 (1994-11-01), None
patent: WO 96/20703 (1996-07-01), None
patent: WO 97/02032 (1997-01-01), None
Andreoli, Thomas E. et al.,Cecil Essentials of Medicine, 4thEdition, W. B. Saunders Company, p. 536, (1997).
Davis, et al., “Aloe Vera and Gibberellin Anti-inflammatory Activity in Diabetes,” Joumal of the American Podiatric Medical Association, 79:1, pp. 24-26, (Jan. 1989).
Loudon, G. Marc,Organic Chemistry, 4thEdition, Oxford University Press, pp. 1343-1348, (2002).
Intemational Search Report in corresponding application PCT/AU02/01083, mailed Oct. 7, 2002.
Ito et al., “New Model of Progressive Non-Insulin-Dependant Diabetes Mellitus in Mice Induced by Streptozotocin,”Biol. Pharm. Bull. 22(9) pp. 988-989 (1999).
Ramasamy et al., “Protein Kinase C and the Sub-sensitivity and Sub-reactivity of the Diabetic Rat Prostate Gland to Noradrenaline,”European Journal of Pharmacology434 pp. 151-161 (2002).
Buu-Hoi, N.P., “Experimental Studies on the Problem of Chemotherapy in Pre-Diabetes,”Med. Pharmacol. 14(6) pp. 576-584 (1966).
Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention, U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) (Feb. 2008).
Wilson et al., “Intensive Insulin Therapy in Critical Care,”Diabetes Care30: 4, 1005-11 (2007).
Wikipedia Entry, “Diabetic Hypoglycemia,” http://en.wikipedia.org/wiki/Diabetic—hypoglycemia , last visited Dec. 22, 2010.
“Antidiabetic Drugs,”The Year's Drug News, Therapeutic Targets, Barcelona: Prous Science, 351-360 (1995).
Benoit et al., “Insulin and Leptin as Adiposity Signals,”Recent Progress in Hormone Research, 59:267-285 (2004).
Cardinal et al., “Increased Susceptibility to Streptozotocin-Induced β-Cell Apoptosis and Delayed Autoimmune Diabetes in Alkylpurine-DNA-N-Glycosylase-Deficient Mice,”Molecular and Cellular Biology, 21:5605-5613 (2001).
Chen et al., “Duration of Streptozotocin-Induced Diabetes Differentially Affects p38-Mitogen-Activated Protein Kinase (MAPK) Phosphorylation in Renal and Vascular Dysfunction,”Cardiovascular Diabetology, 4:3 (2005) Abstract.
Children's Medical Center at the University of Virginia,Pediatric Pharmacotherapy, 2:1-4 (1996).
DCCT/EDIC Research Group, “Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years After a Trial of Inensive Therapy,”New England Jour. Med., 342:381-389 (2000).
“Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications,” World Health Org., Dept. of Noncommunicable Disease Surveillance, Geneva 21-22 (1999).
Dorland's Illustrated Medical Dictionary, 25thEd., Philadelphia: W.B. Saunders, 1673.
Express Scripts, Inc., http://www.drugdigest.org/DD/PrintablePages/Comparisons/1,20038,8-21,00.html, printed on Mar. 8, 2005.
“Glucophage,”Glucolet Encaps, 1561 (1996).
Heilbron, I.M. (Ed.),Dictionary of Organic Compounds, 6thEd, London: Chapman and Hall, 2741-2747 (1996).
Loudon,Organic Chemistry, 3rdEd. Redwood City, CA: Benjamin/Cummings Publishing Co., Inc., 1343-1348 (1995).
Loudon,Organic Chemistry, 3rdEd. Redwood City, CA: Benjamin/Cummings Publishing Co., Inc., 131, 739 (1995).
MacRury et al., “Changes in Phagocytic Function With Glycaemic Control in Diabetic Patients,”J. Clin. Pathol., 42:1143-1147 (1989).
Mander, Twenty Years of Gibberellin Research, Nat. Prod. Rep., 20, pp. 49-69 (2003).
March, J.,Advanced Organic Chemistry, 4thEd. New York: J. Wiley and Sons, 423 (1992).
Mims Annual, “Hypoglycaemic Agents,” 612, 614-618, 620 (2003).
Ramasamy et al., “Protein Kinase C and the Sub-Sensitivity and Sub-Reactivity of the Diabetic Rat Prostate Gland to Noradrenaline,”European Journal of Pharmacology, 434:151-161 (2002).
Reeve et al., An Assessment of Gibberellin Structure-Activity Relationships, J. of Exper. Bot., 25(85), pp. 431-45 (1974).
Reichard et al., “The Effect of Long-Term Intensified Insulin Treatment on the Development of Microvascular Complications of Diabetes Mellitus”,New England Jour. Med., 329:304-309 (1993).
Roberts, J. et al.,Basic Principles of Organic Chemistry, New York: W. A. Benjamin and Co., 148 (1964).
Rolandsson et al., “Streptozotocin Induced Diabetes in Minipig: A Case Report of a Possible Model for Type 1 Diabetes,”Autoimmunity, 35:261-264 (2002) Abstract.
Sharp,The Penguin Dictionary of Chemistry, 5thEd., Harmondsworth, England: Penguin Books, 193 (1983).
Shurtz-Swirski et al., “Involvement of Peripheral Polymorphonuclear Leukocytes in Oxidative Stress and Inflammation in Type 2 Diabetic Patients,”Diabetes Care, 24:104-110 (2001).
Sweetman, S.C. (Ed.), “Antidiabetics,”Martindale, The Complete Drug Reference, 33rd Ed., London: Pharmaceutical Press, 315-316.
Uvarov et al.,A Dictionary of Science, 4thEd., Harmondsworth, England: Penguin Books, 169 (1971).
Webster's Collegiate Dictionary, 855 (11thed. 2003).
Yang et al., Effects of Gibberellins on Seed Germination of Phytochrome-Deficient Mutants ofArabidopsis thaliana, Plant Cell Physiol., 36(7), pp. 1205-1211 (1995).
Darby et al., “Apoptosis is Increased in a Model of Diabetes-Impaired Wound Healing in Genetically Diabetic Mice”.Int. J. Biochem. Cell Biol., vol. 29 (1), pp. 191-200, 1997.

Affiliated with

Also associated with

Rating

Preparation and diabetic use of Gibberellins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Preparation and diabetic use of Gibberellins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preparation and diabetic use of Gibberellins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2738448